Endocyte's radioligand therapy reduces PSA in CRPC patients

Newly released data showed that 177Lu-PSMA-617 from Endocyte Inc. (NASDAQ:ECYT) reduced prostate-specific antigen (PSA; KLK3) levels in a

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE